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Cigarette smoking and cannabis use are equally
strongly associated with psychotic-like experiences:
a cross-sectional study in 1929 young adults
W. A. van Gastel1*, J. H. MacCabe2, C. D. Schubart1, A. Vreeker1, W. Tempelaar1, R. S. Kahn1
and M. P. M. Boks1
1Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Department of Psychiatry, Utrecht, The Netherlands
2Department of Psychosis Studies, Institute of Psychiatry, King’s College London, UK
Background. Cannabis use is associated with increased risk for psychotic-like experiences (PLEs) and psychotic disorders.
It remains unclear whether this relationship is causal or due to confounding.
Method.Atotal of 1929youngadults aged18–30yearsparticipated inanationwide internet-based survey inTheNetherlands
and gave information on demographics, substance use and parental psychiatric illness and completed the Community
Assessment of Psychic Experiences (CAPE).
Results.Cigarette smoking and cannabis use were equally strongly associated with the frequency of PLEs in a fully adjusted
model (β=0.098 and 0.079 respectively, p<0.05). Cannabis usewas associatedwith distress fromPLEs in amodel adjusted for
an elaborate set of confounders excluding smoking (β=0.082, p<0.05). However, when cigarette smokingwas included in the
model, cannabis use was not a signiﬁcant predictor of distress from PLEs. Cigarette smoking remained associated with dis-
tress from PLEs in a fully adjusted model (β=0.107, p<0.001).
Conclusions. Smoking is an equally strong independent predictor of frequency of PLEs asmonthly cannabis use. Our results
suggest that the association between moderate cannabis use and PLEs is confounded by cigarette smoking.
Received 25 October 2012; Revised 19 January 2013; Accepted 24 January 2013; First published online 18 February 2013
Key words: Cannabis use, confounding, nicotine, psychosis, psychotic-like experiences, reverse causality, risk, smoking.
Introduction
Cannabis use has been implicated as a risk factor
for psychotic symptoms, ranging from subclinical
psychotic-like experiences (PLEs) to clinically deﬁned
schizophrenia (Andreasson et al. 1987; Arseneault
et al. 2002; van Os et al. 2002; Fergusson et al. 2003;
Henquet et al. 2005; Moore et al. 2007; Schubart et al.
2011; van Gastel et al. 2012b). There is evidence of a
dose–response effect: heavy and long-term cannabis
use and an initiation of use before the age of 16 years
are associated with an elevated rate of PLEs
(Arseneault et al. 2002; Monshouwer et al. 2006;
Schubart et al. 2011; van Gastel et al. 2012a). Moreover,
the onset of psychosis is earlier in cannabis-using
patients (Large et al. 2011) and cannabis use may
exacerbate symptoms in patients with established psy-
chosis (Mullin et al. 2012).
Although the association between cannabis use and
psychotic symptoms is ﬁrmly established, the nature of
the relationship remains subject to debate (Murray
et al. 2007). Several underlying mechanisms have
been proposed, such as the persistence of normally
transient cannabis-induced psychotic symptoms
(Cougnard et al. 2007), an adverse impact on the devel-
oping endo-cannabinoid and/or dopaminergic system
(Caspi et al. 2005; Henquet et al. 2006; Bossong &
Niesink, 2010; Costas et al. 2011) and reverse causality,
whereby individuals with PLEs are more likely to start
using cannabis in an attempt to ‘self-medicate’ their
distress (Henquet et al. 2005; Macleod et al. 2007). A
further possibility is that the association between can-
nabis consumption and psychotic symptoms could
arise through confounding (Macleod & Hickman,
2006; Macleod et al. 2007; van Gastel et al. 2012a). A
substantial overlap exists between risk factors for can-
nabis use and mental health problems in young adoles-
cents (van Gastel et al. 2012a), and in many studies the
association between cannabis use and mental health
problems is diminished following adjustment for con-
founders (e.g. Macleod et al. 2004; Monshouwer et al.
2006; van Gastel et al. 2012b).
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Tobacco smoking may be such a confounder.
Nicotine dependency is associated with psychotic
symptoms: two longitudinal studies found a dose–
response relationship between cigarette smoking in
adolescence and later psychotic symptoms in the gen-
eral population (Weiser et al. 2004; Sørensen et al. 2011).
Furthermore, two cross-sectional studies found an
association between cigarette smoking and psychotic
symptoms (Degenhardt & Hall, 2001; Wiles et al.
2006) and the majority (70–85%) of patients with
schizophrenia smoke cigarettes (Lasser et al. 2000;
Ziedonis et al. 2008). Additionally, cannabis use and
cigarette smoking are strongly correlated (Agrawal
et al. 2012) and, in most European countries, cannabis
is usually consumed in combination with tobacco.
Thus, the question arises as to what extent the relation-
ship between cannabis use and PLEs is inﬂuenced by
cigarette smoking. In a large cross-sectional sample
we addressed this issue by comparing two elaborately
adjusted models of the association between cannabis
use and frequency of PLEs and associated distress,
both with and without adjustment for cigarette smok-
ing.
Method
Participants
The data were collected in The Netherlands over the
period from August 2006 to April 2011 using a
research website designed for this purpose (Vreeker
et al. 2013). Participants were recruited through adver-
tisements on websites, chat clients, college intranet
sites, during college introduction periods and in ‘coffee
shops’ (licensed retailers of cannabis products). On
the website it was explained that the aim of the
study was to investigate the potential effect of cannabis
use on strange experiences. As an incentive, partici-
pants had a chance of winning a prize, ranging from
a Hawaiian garland and credit for online shopping to
a parachute jump or a laptop computer. Web-based
questionnaires covered sociodemographic character-
istics, lifestyle, social environment and psychosocial
functioning. To detect random answering and auto-
mated answers by internet robots, veriﬁcation items
were included. All participants gave informed consent
online and the study was approved by the ethics com-
mittee of the University Medical Center Utrecht.
Measurements
PLEs. The Community Assessment of Psychic Experi-
ences (CAPE) was used to assess lifetime PLEs
(Stefanis et al. 2002; Konings et al. 2006). The CAPE
has discriminative validity in community samples
(Stefanis et al. 2002; Konings et al. 2006). Each item
measures the frequency and associated distress of
psychotic experiences, each rated on a four-point
scale ranging from ‘never’/‘not distressed’ (1) to ‘nearly
always’/‘very distressed’ (4). If the frequency was
‘never’, distress was not inquired about and was
automatically set to zero. The scores were rescaled by
subtracting the minimum score [as suggested for the
Positive and Negative Syndrome Scale (PANSS) instru-
ment by Obermeier et al. (2010)], such that a person
reporting no psychotic symptoms scored zero. Scores
on the Frequency and Distress scales were used as out-
come measures and a post-hoc analysis was performed
on the Positive, Negative and Depressive subscales.
The subscales comprise the frequency of experiences
in these symptoms dimensions (but not associated
distress).
Cannabis use. Individuals who reported that they
had ever used cannabis on a monthly basis were
classiﬁed as cannabis users; ever use of cannabis at
least weekly was coded as heavy use. Subjects were
also asked at what age they started using cannabis.
Cigarette smoking. Cigarette smoking was deﬁned as
daily smoking for at least 1 month during the past
year.
Other covariates. Heavy alcohol use was deﬁned as
>21 drinks/week for men and >14 for women, accord-
ing to the Dutch directive for alcohol consumption
(de Beer & van de Glind, 2009). Lifetime use of any
other illicit substances was recorded. Nationality was
based on the country of birth of the grandparents; sub-
jects with two or more grandparents born outside The
Netherlands were deﬁned as non-native. Education
was coded according to the three educational tracks
in Dutch secondary schools and higher education:
vocational, polytechnic and scientiﬁc. Treatment of
one or both parents for a mental disorder, including
addiction, psychotic and affective symptoms, was
also included. Participants were asked whether a
parent was ever treated for a mental disorder, either
with medication, hospitalization or another form of
professional care.
Data analysis
All analyses were carried out with SPSS version 20.0
(SPSS Inc., USA). Listwise exclusion was applied
for missing values. Linear regressions were carried
out, with the CAPE Frequency and Distress scores as
outcome measures after veriﬁcation of statistical
assumptions using scatterplots of the residuals. The as-
sociation between cannabis use and CAPE Frequency
and Distress was assessed, ﬁrst in a crude model and
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second in a model adjusting for confounders age and
gender, plus other potential confounders that were
associated with cannabis use and the outcome
measures at p<0.05. Third, cigarette smoking was
added to both crude and fully adjusted models. The
interaction between cannabis use and smoking was
also investigated. Lastly, post-hoc analyses were per-
formed with the Positive, Negative and Depressive
subscales as outcome measures, and the effect of fre-
quency of cannabis use was explored.
Results
There were 27 missing values for ethnicity, 22 for
mental disorder of parents and eight for educational
track. Listwise exclusion of these resulted in a sample
of 1929 adolescents aged 18–30 years, 947 (49.1%)
male. Table 1 lists sample characteristics, stratiﬁed by
monthly cannabis use: non-users had used cannabis
never or infrequently, users had consumed cannabis
at least monthly at some point in their lives. Groups
differed signiﬁcantly on all characteristics. About
one-third of the total sample (36.5%) had never
used cannabis, another 9.3% less than yearly. Among
cannabis users, 50.3% started using between the ages
of 15 and 17 years; 30.3% of them started using before
the age of 15. The proportion of daily cigarette smokers
was 39% overall, and was 70.9% among cannabis
users.
Association between cannabis use and PLEs
The regression coefﬁcients (β) and p values for the
association between cannabis use and psychotic
experiences, as measured by the CAPE Frequency
and Distress scores, are shown in Table 2. The results
show that cannabis use was related to the CAPE
Frequency and Distress scores, even when an elaborate
set of confounders was taken into account (β=0.123,
p<0.001 and β=0.082, p<0.05 respectively).
Association between cannabis use, smoking and
PLEs
The association between cannabis use, smoking and
frequency of PLEs, as measured by the CAPE, is
shown in Table 2. Both cannabis use and smoking
were associated with frequency of PLEs, in a crude
(β=0.110 and β=0.128 respectively, p<0.001) and also
in a fully adjusted model (β=0.079, p<0.05 and β=
0.098, p<0.01 respectively). No signiﬁcant interaction
effects were found for cannabis and smoking, although
we had limited power to ﬁnd such an effect.
Association between cannabis use, smoking and
distress from PLEs
The association between cannabis use, smoking and
distress from PLEs, as measured by the CAPE, is also
shown in Table 2. Cigarette smoking was signiﬁcantly
associated with distress from PLEs, in both a crude
(β=0.132, p<0.001) and a fully adjusted model (β=
0.107, p<0.001). Cannabis use was not signiﬁcantly
associated with distress from PLEs when cigarette
smoking was included as a covariate, either in a
crude or in a fully adjusted model. Again, no signiﬁ-
cant interaction effects were found for cannabis and
smoking, although we had limited power to ﬁnd
such an effect.
Association between cannabis use, smoking and
CAPE Positive, Negative and Depressive subscales
Cannabis use and smoking were signiﬁcantly as-
sociated with the score on the CAPE Positive subscale,
in a crude (β=0.135, p<0.001 and β=0.107, p<0.001
respectively) and in an adjusted model (β=0.117, p<
0.001 and β=0.082, p<0.01 respectively). For the score
on the CAPE Negative subscale, the association with
cannabis use was only signiﬁcant in a crude model
alongside smoking (β=0.102, p<0.001), whereas smok-
ing remained signiﬁcantly associated in the fully
Table 1. Sample characteristics of the total study sample (n=1929), stratiﬁed by cannabis use
Characteristic
Total
(n=1929)
Non-users
(n=1000)
Users
(n=929) χ2 or t p value
Age (years), mean (S.D.) 21.6 (2.6) 21.2 (2.3) 22.0 (2.8) −6.345 <0.001
Male gender, n (%) 947 (49.1) 378 (37.8) 569 (61.2) 106.0 <0.001
52 grandparents born outside The Netherlands, n (%) 290 (15.0) 87 (8.7) 203 (21.9) 65.2 <0.001
Low level of education, n (%) 585 (30.3) 198 (19.8) 387 (41.7) 108.9 <0.001
Parent(s) treated for mental health problems, n (%) 493 (25.6) 198 (19.8) 295 (31.8) 36.2 <0.001
Cigarette smoking, n (%) 762 (39.5) 103 (10.3) 659 (70.9) 741 <0.001
Regular alcohol consumption, n (%) 1656 (85.8) 810 (81.0) 846 (91.1) 40.2 <0.001
Other illicit substance use ever, n (%) 707 (36.7) 59 (5.9) 648 (69.8) 845.7 <0.001
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adjusted model (β=0.096, p<0.01 crude and β=0.080, p
<0.01 adjusted). Cannabis use was only associated
with the score on the CAPE Depressive subscale in
a crude model without smoking (β=0.088, p<0.001);
smoking remained signiﬁcantly associated in the ad-
justed model (β=0.129, p<0.001 crude and β=0.086,
p<0.01 adjusted).
Frequency of cannabis use
For heavy cannabis use, the association with frequency
of PLEs was the same as for monthly cannabis use:
heavy cannabis use was associated with frequency
of PLEs in a crude model without cigarette smoking
(β=0.198, p<0.001), alongside cigarette smoking (β=
0.124, p<0.001) and in a fully adjusted model (β=
0.100, p<0.01). Smoking was associated with frequency
of PLEs in a crude model with only heavy cannabis use
(β=0.122, p<0.001), and also in a fully adjusted model
(β=0.093, p<0.01).
For distress, however, heavy cannabis use was only
signiﬁcantly associated with the outcome in a crude
model (β=0.144, p<0.001) without smoking, but not
in the models adjusting for (1) cigarette smoking and
(2) other confounders (at p<0.025). Smoking remained
associated with distress from PLEs alongside heavy
cannabis use (β=0.125, p<0.001 crude and β=0.100,
p<0.01 adjusted).
Discussion
In a large sample of young adults aged 18 to 30 years,
we found that cigarette smoking was as strongly as-
sociated as cannabis use with frequency of PLEs, and
even more strongly with distress from PLEs. When
cigarette and cannabis smoking were included in the
same model, cigarette but not cannabis smoking was
associated with distress from psychotic symptoms.
This suggests that the relationship between cannabis
use and distress from PLEs is confounded by cigarette
smoking. Weekly cannabis use, however, was associ-
ated with distress from PLEs alongside cigarette
smoking in a crude model, suggesting that, at higher
frequencies of cannabis use, the confounding by ciga-
rette smoking is less pronounced.
Cigarette smoking and PLEs
The associations we found for cigarette smoking echo
previous studies. Degenhardt & Hall (2001) found
that both cannabis use and cigarette smoking are
associated with a range of mental health problems,
including psychosis. Saha et al. (2011) showed that
individuals who smoke cigarettes were more likely to
endorse delusional-like experiences, as were those
who had been diagnosed with cannabis dependence
or those who had started cannabis use before the age
Table 2. Standardized regression coefﬁcients (β) and p values for the association between monthly cannabis use, daily smoking and
Community Assessment of Psychic Experiences (CAPE) scores for crude and adjusted models. For the adjusted models, associations between all
factors and CAPE scores are also displayed. βs with a p value below 0.05 are shown in italics
Model Predictor Frequency, β (p) Distress, β (p)
Monthly cannabis use Crude Cannabis use 0.190 (<0.001) 0.132 (<0.001)
Adjusted Cannabis use 0.123 (<0.001) 0.082 (0.008)
Age −0.033 (0.133) −0.030 (0.186)
Male gender −0.048 (0.034) −0.078 (<0.001)
Foreign ethnicity 0.088 (<0.001) 0.072 (0.002)
Low education 0.062 (0.006) 0.033 (0.148)
Heavy alcohol use −0.006 (0.793) −0.017 (0.463)
Other illicit substances (ever) 0.050 (0.093) 0.056 (0.063)
Parent(s) treated for mental problems 0.144 (<0.001) 0.141 (<0.001)
Monthly cannabis use
and daily smoking
Crude Cannabis use 0.110 (<0.001) 0.050 (0.082)
Smoking 0.128 (<0.001) 0.132 (<0.001)
Adjusted Cannabis use 0.079 (0.017) 0.034 (0.310)
Smoking 0.098 (0.001) 0.107 (<0.001)
Age −0.036 (0.109) −0.032 (0.152)
Male gender −0.044 (0.054) −0.082 (<0.001)
Foreign ethnicity 0.089 (<0.001) 0.072 (0.001)
Low education 0.048 (0.039) 0.017 (0.453)
Heavy alcohol use −0.010 (0.644) −0.022 (0.342)
Other illicit substances (ever) 0.030 (0.316) 0.034 (0.260)
Parent(s) treated for mental problems 0.139 (<0.001) 0.136 (<0.001)
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of 16 years. In parallel with our ﬁndings, they also
showed that the association between daily smoking
and delusional-like experiences persisted after adjust-
ment for other risk factors whereas the association
with cannabis use dependence did not.
The implications of our ﬁndings with respect to
clinical psychosis remain unknown. Distress has been
found to be an important predictive factor of transition
from subclinical psychotic experiences to clinical
psychosis (Krabbendam et al. 2005; Fusar-Poli et al.
2012). In the absence of further data we can only
speculate whether the association of distress from
PLEs with smoking signiﬁes a causal relationship or
whether this risk factor merely identiﬁes those who
are at risk.
The association between cigarette smoking and PLEs
can be explained in several ways. First, cigarette smok-
ing could increase the risk for PLEs through a bio-
logical mechanism. In support of this, Brody et al.
(2004) showed that smoking causes acute dopamine
release in the ventral striatum and nicotinergic cholin-
ergic neurotransmission was reported to be related to
schizophrenia (Dean et al. 2003; Ripoll et al. 2004).
A second possibility is that nicotine is taken in an
attempt to alleviate psychotic-like symptoms. There is
some evidence that nicotine may alleviate symptoms
associated with psychotic disorders (Punnoose &
Belgamwar, 2006) as it improves negative symptoms
in psychotic patients and cognitive functioning in
both healthy subjects and psychotic patients (Dalack
et al. 1998; Lyon, 1999; Barr et al. 2008; Jubelt et al.
2008; Wignall & de Wit, 2011). However, research in
patients with schizophrenia has shown an association
between nicotine dependence and worse psychotic
symptoms (Kelly & McCreadie, 1999; Krishnadas
et al. 2012). A third (slightly more remote) possibility
is that PLEs result from nicotine withdrawal effects,
as this has been observed in cases of psychotic patients
(Dalack & Meador-Woodruff, 1996).
A fourth possibility is that the association between
cigarette smoking and PLEs could be due to confound-
ing by one or more other factors. In other words, indi-
viduals who are prone to PLEs are also prone to smoke
cigarettes. Psychosocial stress increases the risk of PLEs
and stress reduction is a frequent reason to smoke
(Mobascher & Winterer, 2008; Compton et al. 2009).
This explanation is supported by our ﬁnding of a
signiﬁcant association between cigarette smoking and
distress associated with PLEs.
Cannabis use and PLEs
Cannabis use has received much attention as a poten-
tial cause of PLEs and psychotic disorders (Macleod
et al. 2004; Moore et al. 2007). Regarding the association
between moderate cannabis use and frequency of
PLEs, our ﬁndings are equivocal. Cannabis use
was associated with frequency scores, also in a fully
adjusted model. This shows that cannabis use is inde-
pendently associated with frequency of PLEs and a
causal relationship is a possibility. However, our
ﬁnding that monthly cannabis use and cigarette smok-
ing were equally strongly associated with frequency
scores argues against a speciﬁc causative effect of
moderate cannabis use on PLEs. Although it remains
possible that nicotine and cannabis are causally related
to PLEs, the non-speciﬁcity of the associations does
suggest that reverse causation or confounding is at
play.
Furthermore, regarding distress from PLEs, our
ﬁndings are not supportive of the view of cannabis
use as a cause of psychotic experiences. Theoretically,
cannabis and tobacco could speciﬁcally reduce the dis-
tress associated with cannabis-induced PLEs. Cannabis
would then still be causally related to PLEs but
the associated distress would be countered through
other pathways by the addition of tobacco. If cannabis
were to cause highly distressing PLEs, however, the
association would persist even after complete adjust-
ment for confounding. However, even with inevitable
residual confounding at play, monthly cannabis use
was not signiﬁcantly associated with distress from
PLEs when combined with smoking in crude and ad-
justed models. This implies that the association
between highly distressing PLEs and cannabis use is
confounded by cigarette smoking, and possibly other
confounders. Regarding the effect of residual confound-
ing on the relationship between early cannabis use
and psychosis-related outcomes, McGrath et al. (2010)
showed that this is unlikely to be the explanation of
this relationship altogether, by applying sibling-pair
analyses.
Of note, a recent meta-analysis (Myles et al. 2012)
concluded that tobacco smoking does not contribute
to an earlier age at onset of psychosis, and hence
should not be viewed as a confounding factor for the
relationship between cannabis use and an earlier age
at onset of psychosis. There are several possible expla-
nations for these seemingly contradictory results. First,
our study focused on subclinical psychotic symptoms,
as opposed to clinical psychosis. Second, because of the
limited number of studies examining the impact of
both substances in the same population, Myles et al.
(2012) were unable to establish the relative impact of
the co-consumption of tobacco and cannabis. In our
sample, we were able to compare the association be-
tween both substances and PLEs. Third, in the current
study we investigated lifetime moderate (monthly)
cannabis use whereas in the meta-analysis by Myles
et al. (2012), studies were included with varying
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thresholds of use, from ‘past or current use’ to a
current cannabis use disorder.
Overall, our ﬁndings ﬁt the hypothesis that individ-
uals who are prone to PLEs, particularly if associated
with high distress, are more inclined to use cannabis.
If this is the case, moderate cannabis use, like cigarette
smoking, could be viewed as a mere indicator of risk
for PLEs, and thus for mental health problems in gen-
eral (Johns & van Os, 2001; Yung et al. 2003; Hanssen
et al. 2005), instead of a causative factor. This view
is consistent with the accumulation of risk factors in
the group of subjects using cannabis at least monthly,
including foreign ethnicity (van Gastel et al. 2012b),
low educational level (Ruhrmann et al. 2010) and
family history of a mental disorder (Mortensen et al.
1999; Mattejat & Remschmidt, 2008).
In contrast to monthly cannabis use, the association
between weekly cannabis use and distress from PLEs
did persist alongside cigarette smoking in a crude
model. This shows that frequency of use might play
a key role in the mechanism underlying the association
and that a causal relationship between cannabis use
and PLEs may exist for higher frequencies of use.
This is in line with the meta-analysis by Myles et al.
(2012). Our ﬁndings are consistent with a model in
which the tendency to use cannabis is associated
with increased levels of PLEs, and heavy use of
cannabis leads to additionally increased psychosis
proneness.
Limitations
A major limitation is that our study is cross-sectional,
precluding ﬁrm conclusions regarding causality.
Nonetheless, the results are in line with longitudinal
studies linking both cannabis use (Arseneault et al.
2002; van Os et al. 2002; Henquet et al. 2005; Rossler
et al. 2012) and cigarette smoking to (subclinical) psy-
chotic symptoms (Degenhardt & Hall, 2001; Weiser
et al. 2004; Wiles et al. 2006; Sorensen et al. 2011).
Furthermore, our data were gathered by self-report
on the internet, possibly leading to either over- or
under-reporting of undesirable behaviour such as
cannabis use. However, studies comparing psycho-
metric and biometric measures of cannabis use (in-
cluding urine and hair tests) show good reliability
of self-report measures (Ledgerwood et al. 2008;
Zaldivar et al. 2009). In addition, advertisements with
cannabis use mentioned as the topic of the study may
have attracted a selection of the population. Although
recent studies have shown that the internet is a suitable
instrument for scientiﬁc research (Meyerson & Tryon,
2003; Gosling et al. 2004; Balter et al. 2005; Ekman
et al. 2006; M. Vleeschouwer et al., unpublished obser-
vations) and potential bias is unlikely to be systematic,
we cannot rule out that our sample is in some way not
representative of the general population.
The CAPE questionnaire inquires after lifetime
psychotic experiences and these may be difﬁcult to
distinguish from acute intoxication effects of cannabis.
There is, however, some evidence that high CAPE
scores associated with acute cannabis intoxication are
also a reﬂection of psychosis proneness (Kahn et al.
2011). In addition, the time of the last cigarette on
the day of participation was not assessed. Further-
more, whereas the time frame for cannabis use was
the same as for the CAPE questionnaire (i.e. lifetime),
that of smoking was the past year, possibly resulting
in an underestimation of the number of smokers.
As in other studies, there was a large overlap be-
tween smoking and cannabis use in our sample
(Lynskey et al. 1998; Degenhardt & Hall, 2001). More-
over, cannabis is usually consumed in combination
with tobacco in The Netherlands. Even so, nearly a
third of cannabis users in this study were non-smokers
of cigarettes. As the threshold for cannabis use was set
to at least once a month ever, the subjects who did not
smoke cigarettes as such had a relatively low intake of
tobacco. In combination with the large sample size,
this did allow us to tease out the relative importance
of these risk factors to a large extent. The consistency
of the ﬁndings in unadjusted and adjusted models
suggests that these ﬁndings are stable.
Because we assessed lifetime use of cannabis in this
study, we were unable to distinguish between current
and past users. Previous research did ﬁnd evidence
for a persisting association between past cannabis
use and current PLEs in adolescents (van Gastel,
2012a). In addition, the way in which cannabis was
consumed was not investigated directly in this study.
Finally, unknown sources of confounding may remain;
although measures of demographic factors and sub-
stance use were available, residual confounding
by extensive behavioural and psychopathological fac-
tors such as attention-deﬁcit hyperactivity disorder,
externalizing behaviour and conduct disorder
(Monshouwer et al. 2006; Karatekin et al. 2010; Lee
et al. 2011; Malcolm et al. 2011) cannot be ruled out.
Factors that may play a role, but that were not
measured, are age at onset of cigarette smoking
(Saha et al. 2011), urbanicity, socio-economic status,
social support and household composition (van
Gastel et al. 2012b).
Despite its limitations, the present study is an im-
portant addition to the existing literature because it
demonstrates that smoking is equally strongly associ-
ated with PLEs as cannabis use. Moreover, the as-
sociation between monthly cannabis use and distress
from PLEs is strongly inﬂuenced by cigarette smoking.
Our ﬁndings are consistent with a model in which
2398 W. A. van Gastel et al.
individuals who are prone to PLEs are more inclined
to smoke cigarettes and use cannabis, and in which
heavy use of cannabis leads to additionally increased
psychosis proneness.
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